Ready for a Closeup:
Differentiating Inadequate Response and Emotional Blunting During Treatment for Major Depressive Disorder
33-YEAR-OLD FEMALE
Inadequate response to therapy
62-YEAR-OLD MALE
Emotional blunting associated with therapy
43-YEAR-OLD FEMALE
Persistent, debilitating symptoms of MDD
Watch this “cinemeducation” video from start to finish for a complete, sequential learning experience OR skip around by clicking on the individual cases listed above to watch each of them in any order that suits your educational needs.
To view for CME credit click hereOverview
Major depressive disorder is not just about feeling “down.” It’s a life-threatening condition that is a leading cause of suicide. Fortunately, there are a variety of effective therapies; however, many patients may have an inadequate response to treatment and others may experience anhedonia or reduced emotional responsiveness (ie, emotional blunting) associated with both selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors (SSRIs/SNRIs).
Do you have questions about the symptoms of emotional blunting or differentiating emotional blunting from inadequate treatment response? What about assessing the effectiveness of different therapies? This innovative “cinemeducation” format is where patient and clinician dialogues come to life to model best practices. Find out how to use measurement-based care for tracking symptoms of depression; assess and manage treatment-related emotional blunting; and involve patients in shared decision making.
Enhance your clinical practices and help your patients find the light again.
Hear More From Our Faculty
Becoming more attuned to emotional blunting
Considering a diagnosis of emotional blunting
Determining a patient's most problematic symptoms
How patients may respond to emotional blunting as a side effect of treatment
Managing comorbidities in patients with MDD
Supporting patients with MDD
LET'S BE BLUNT:
Collaborating with Patients with Major Depressive Disorder to Achieve Full Functional Recovery
Join Anita Clayton, MD from the University of Virginia School of Medicine, Roger McIntyre, MD, FRCPC, from the University of Toronto, Michael Thase, MD, from the Perelman School of Medicine at the University of Pennsylvania! Discussion will focus on the latest evidence for treatment for MDD, including growing awareness around the recognition and impact of emotional blunting. Faculty will also discuss the importance of shared decision making with patients, while adjusting medication dose or switching treatments.
Special thanks to Anita Clayton, MD, Roger McIntyre, MD, FRCPC, Michael Thase, MD, and The Mighty whose guidance and expertise were used in the development of this educational resource.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Educational Resources:
- LET'S BE BLUNT: Collaborating With Patients With Major Depressive Disorder to Achieve Full Functional Recovery
- Christensen MC, Ren H, Fagiolini A. Emotional blunting in patients with depression. Part I: clinical characteristics. Ann Gen Psychiatry. 2022;21:10.
- Goodwin GM, Price J, De Bodinat J, Laredo J. Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord. 2017;221:31-5.
- Hong RA, Murphy JK, Michalak EE, et al. Implementing measurement-based care for depression: practical solutions for psychiatrists and primary care physicians. Neuropsychiatr Dis Treat. 2021;17:79-90.
- Ma H, Cai M, Wang H. Emotional blunting in patients with major depressive disorder: a brief non-systematic review of current research. Front Psychiatry. 2021;12:792960.
- Mills NT, Sampson E, Fourrier C, Baune BT. Clinical switching strategies of various antidepressants to vortioxetine in the PREDDICT trial. Int J Neuropsychopharmacol. 2021;24(4):314-21.
- Siniscalchi KA, Broome ME, Fish J, et al. Depression screening and measurement-based care in primary care. J Prim Care Community Health. 2020;11:2150132720931261.
- US Preventive Services Task Force. Screening for depression and suicide risk in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(23):2057-67.
- Emotional blunting with antidepressants
- Oxford Depression Questionnaire for tracking emotional blunting
- Effectiveness of vortioxetine on emotional blunting
- Implementing measurement-based care for depression
- Empowering tools for your patients